Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.
BACKGROUND
Apolipoprotein E varepsilon4 (APOE varepsilon4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE varepsilon4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE varepsilon4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI).


METHODS
A total of 516 aMCI participants aged 55-90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE varepsilon4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period.


RESULTS
APOE varepsilon4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE varepsilon4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini-Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale.


CONCLUSIONS
These findings demonstrate that APOE varepsilon4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE varepsilon4 status needs to be accounted for in treatment trials of MCI.
Whitehair
Danielle C
DC
Department of Neurosciences, University of California, San Diego, CA, USA.
Sherzai
Abdullah
A
Emond
Jennifer
J
Raman
Rema
R
Aisen
Paul S
PS
Petersen
Ronald C
RC
Fleisher
Adam S
AS
D000368:Aged; D000369:Aged, 80 and over; D053327:Apolipoprotein E4 / Q000235:genetics*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy / Q000235:genetics*; D018450:Disease Progression; D000077265:Donepezil; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010880:Piperidines / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D014810:Vitamin E / Q000627:therapeutic use
D053327:Apolipoprotein E4; D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D014810:Vitamin E; D000077265:Donepezil
Lancet Neurol. 2006 Jun;5(6):468-9
16713915
Dement Geriatr Cogn Disord. 2008;26(2):101-8
18617739
J Geriatr Psychiatry Neurol. 1999 Winter;12(4):168-79
10616864
Science. 1993 Aug 13;261(5123):921-3
8346443
Arch Neurol. 1992 Dec;49(12):1253-8
1449404
JAMA. 1995 Apr 26;273(16):1274-8
7646655
Neurology. 2004 Jun 8;62(11):1990-5
15184602
Am J Psychiatry. 1984 Nov;141(11):1356-64
6496779
Neurology. 1993 Nov;43(11):2412-4
8232972
Neurology. 2007 May 8;68(19):1588-95
17287448
Int Psychogeriatr. 1996 Summer;8(2):195-203
8994890
Neurology. 1996 Jan;46(1):149-54
8559365
N Engl J Med. 2005 Jun 9;352(23):2379-88
15829527
Arch Neurol. 2007 Sep;64(9):1306-11
17846270
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Neurology. 2005 Jun 14;64(11):1853-9
15955933
Psychol Aging. 2002 Jun;17(2):194-208
12061406
Arch Neurol. 2005 Jun;62(6):975-80
15956169
Int J Geriatr Psychiatry. 2000 Apr;15(4):363-72
10767737
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13-21
9236948
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6820-5
19346482
J Neurol Neurosurg Psychiatry. 2005 Nov;76(11):1479-84
16227534
Arch Neurol. 2004 Jan;61(1):59-66
14732621
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9
9236950
Arch Neurol. 1999 Mar;56(3):303-8
10190820
J Med Genet. 2002 Sep;39(9):639-43
12205106
J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):429-38
16306154
Psychol Aging. 2004 Jun;19(2):367-71
15222832
J Am Geriatr Soc. 2007 Nov;55(11):1777-85
17979899
Neurology. 2004 Sep 14;63(5):816-21
15365129
Neurology. 2001 May 8;56(9):1133-42
11342677
Am J Psychiatry. 1982 Sep;139(9):1136-9
7114305
Neurology. 1984 Jul;34(7):939-44
6610841
Brain. 2008 May;131(Pt 5):1252-8
18334538
Neurosci Lett. 2002 May 10;324(1):74-6
11983298
Ageing Res Rev. 2002 Jun;1(3):345-65
12067591
Neurology. 1999 Jul 13;53(1):201-7
10408560
Neurology. 2006 Mar 28;66(6):828-32
16567698
CNS Spectr. 2008 Jan;13(1):45-53
18204414
Arch Neurol. 2002 Jul;59(7):1154-60
12117364
J Geriatr Psychiatry Neurol. 2005 Dec;18(4):196-201
16306239
Neurology. 2009 Apr 28;72(17):1487-94
19339712
Neurology. 2008 Jan 15;70(3):191-9
18195264
Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):379-86
11598309